Andree Blaukat

This inventor holds 39 USPTO granted patents and 3 published patent applications, plus 22 CIPO patents and 29 EPO patents, primarily in Kinase Inhibitors. Top assignees: Merck Patent Gmbh, Merck Patent Gesellschaft MIT Beschrankter Haftung, Merck Patent Gesellschaft. Active years: 2009-2016.

USPTO Granted Patents = 39 (Patent Applications = 3)

% Patents Active = 38.5

CIPO Patents = 22

EPO Patents = 29 (Patent Applications = 23)

Average Co-Inventor Count = 4.0

ph-index = 8

Forward Citations = 205(Granted Patents)

Location History:

Muehltal, DE (2009 - 2016)
Schriesheim, DE (2012 - 2016)

Company Filing History:

Merck Patent Gesellschaft MIT Beschrankter Haftung

patents

1 out of 121

Merck Patent Gesellschaft

patents

4. 1 out of 100

Merck Patent Gesellschaft MIT Beschraenkter Haftung

patents

Years Active: 2009-2016

Loading Chart...

Areas of Expertise:

Pyrimidinyl Derivatives

Pyridazinone Derivatives

Kinase Inhibitors

Azaheterocyclic Compounds

Piperidine Derivatives

Thiazole Derivatives

Triazole Derivatives

Tumor Treatment

Tyrosine Kinase Modulators

Benzothiazolone Derivatives

Bicyclic Triazole

Aryl Ether Pyridazinone

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9403799 - Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase (2016-08-02),

2. 9376426 - Pyridazinone derivatives (2016-06-28),

3. 9284300 - Pyridazinone derivatives (2016-03-15),

4. 9221806 - 2-(heterocyclylbenzyl)pyridazinone derivatives (2015-12-29),

5. 9062029 - Pyrimidinyl pyridazinone derivatives (2015-06-23),

6. 8927540 - Pyridazinone derivatives (2015-01-06),

7. 8921357 - Pyridazinone derivatives (2014-12-30),

8. 8877751 - Benzothiazolone derivatives (2014-11-04),

9. 8859581 - Azaheterocyclic compounds as kinase inhibitors (2014-10-14),

10. 8859547 - Pyridazinone derivatives (2014-10-14),

11. 8853211 - Pyridazinone derivatives (2014-10-07),

12. 8791111 - Piperidine and piperazine derivatives (2014-07-29),

13. 8754097 - Piperidine and piperazine derivatives (2014-06-17),

14. 8658643 - Pyrimidinyl pyridazinone derivatives (2014-02-25),

15. 8637518 - Pyridazinone derivatives (2014-01-28),

Title: The Innovative Mind of Andree Blaukat

Introduction

Andree Blaukat, based in Schriesheim, Germany, is a prolific inventor with a remarkable portfolio of 39 patents. His contributions to the field of biotechnology, particularly in cancer treatment, have made significant strides in medical research and therapeutic development.

Latest Patents

Among his latest innovations are groundbreaking patents focusing on Pyrimidinyl-pyridazinone derivatives, designed for treating diseases influenced by met kinase inhibition. These compounds are specifically crafted to act as inhibitors of tyrosine kinases, especially Met kinase, showcasing their application in treating tumors. Another noteworthy patent features pyridazinone derivatives, which are similarly classified as inhibitors of tyrosine kinases with potential applications in oncology.

Career Highlights

Andree Blaukat has established a notable career within prestigious companies. He has contributed his expertise at Merck Patent GmbH and Merck Patent Gesellschaft mit beschränkter Haftung, where he has been instrumental in developing therapeutic innovations. His work has not only advanced scientific understanding but has also paved the way for new treatments that may enhance patient care.

Collaborations

Throughout his career, Blaukat has had the opportunity to collaborate with esteemed colleagues, including Oliver Schadt and Dieter Dorsch. These partnerships have driven innovation and have expanded the scope of research in their respective fields.

Conclusion

Andree Blaukat's work exemplifies the spirit of innovation and dedication in the realm of biotechnology. With his extensive patent portfolio and commitment to advancing medical science, he continues to inspire future generations of inventors and researchers in the pursuit of groundbreaking solutions.